Cargando…
Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature
BACKGROUND: In patients with advanced hepatocellular carcinoma (HCC), the multikinase inhibitor sorafenib is the only systemic treatment that has been shown to increase overall survival. However, similar to other tyrosine kinase inhibitors, most patients achieve disease stabilisation radiologically,...
Autores principales: | Atkin, Catherine, Earwaker, Philip, Pallan, Arvind, Shetty, Shishir, Punia, Pankaj, Ma, Yuk Ting |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307848/ https://www.ncbi.nlm.nih.gov/pubmed/28193171 http://dx.doi.org/10.1186/s12876-017-0585-x |
Ejemplares similares
-
Non-secretion of AFP and neutrophil lymphocyte ratio as predictors for survival in hepatocellular carcinoma patients treated with sorafenib: a large UK cohort
por: Afshar, Mehran, et al.
Publicado: (2018) -
The potential of PIVKA-II as a treatment response biomarker in hepatocellular carcinoma: a prospective United Kingdom cohort study
por: Sagar, Vandana M., et al.
Publicado: (2021) -
Innate and Adaptive Immunopathogeneses in Viral Hepatitis; Crucial Determinants of Hepatocellular Carcinoma
por: Zaki, Marco Y. W., et al.
Publicado: (2022) -
Sorafenib-Related Adverse Events in Predicting the Early Radiologic Responses of Hepatocellular Carcinoma
por: Lee, Shou-Wu, et al.
Publicado: (2019) -
Well-Controlled Viremia Predicts the Outcome of Hepatocellular Carcinoma in Chronic Viral Hepatitis Patients Treated with Sorafenib
por: Kuo, Yuan-Hung, et al.
Publicado: (2022)